Since hepatocyte growth factor (HGF) is the sole ligand for MET [54] and is enriched in the tumor microenvironment [55], we first evaluated the function of MET on phosphorylating and activating STAT5A with the treatment of HGF in both LNCaP and C42B cells. The gene discussed is HGF; the disease is neoplasm.